Thermo Fisher Launches SuperScript V Reverse Transcriptase

Thermo Fisher Scientific has introduced Invitrogen SuperScript V Reverse Transcriptase, a next-generation engineered enzyme designed to make the critical step of converting RNA to cDNA faster, easier and more flexible.

Conventional workflows commonly require careful RNase-free handling of RNA, cold storage of samples and reagents, and multi-component reaction setup. SuperScript V combines strong performance with room-temperature stability and simpler setup. With room-temperature stability, labs can assemble and hold reactions for up to 24 hours, so those batching large sets or running automated systems can prep in advance without performance loss. That flexibility, combined with reaction times as short as 1 to 10 minutes, lets labs move through more samples with less setup time.

Available as a standalone enzyme and in ready-to-use master mix formats, it supports workflows ranging from individual experiments to high-throughput and automated cDNA synthesis.

“Our goal is to empower researchers to move from sample to insights faster and with greater confidence,” said Pawan Singh, vice president and general manager, molecular biology, Thermo Fisher Scientific. “With SuperScript V, we’ve taken what researchers have trusted about SuperScript for decades and redefined what’s possible with faster, more flexible and highly stable RNA-to-cDNA synthesis.”